Ping Ying Pan

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. pmc Advancements in immune tolerance
    Ping Ying Pan
    Department of Gene and Cell Medicine, Mount Sinai School od Medicine, New York, NY 10029, USA
    Adv Drug Deliv Rev 60:91-105. 2008
  2. pmc Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer
    Ping Ying Pan
    Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    Cancer Res 70:99-108. 2010
  3. ncbi request reprint In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery
    Ping Ying Pan
    Carl C Icahn Institute for Gene Therapy and Molecular Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cancer Immunol Immunother 53:17-25. 2004
  4. doi request reprint Myeloid-derived suppressor cells prevent type 1 diabetes in murine models
    Bingjiao Yin
    Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Immunol 185:5828-34. 2010
  5. ncbi request reprint Role of immature myeloid Gr-1+ cells in the development of antitumor immunity
    Qingsheng Li
    Carl C Icahn Institute for Gene Therapy and Molecular Medicine, Mount Sinai School of Medicine, New York, New York, USA
    Cancer Res 64:1130-9. 2004
  6. ncbi request reprint NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation
    Dongping Xu
    Carl C Icahn Institute for Gene Therapy and Molecular Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Cancer 109:499-506. 2004
  7. doi request reprint Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells
    Zuping Zhou
    Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    Stem Cells 28:620-32. 2010
  8. pmc Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function
    Ping Ying Pan
    Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Blood 111:219-28. 2008
  9. doi request reprint The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies
    Junko Ozao-Choy
    Departments of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York, USA
    Cancer Res 69:2514-22. 2009
  10. pmc Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy
    Samuel Eisenstein
    Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cancer Res 73:5003-15. 2013

Collaborators

Detail Information

Publications16

  1. pmc Advancements in immune tolerance
    Ping Ying Pan
    Department of Gene and Cell Medicine, Mount Sinai School od Medicine, New York, NY 10029, USA
    Adv Drug Deliv Rev 60:91-105. 2008
    ..This review briefly summarizes the major tolerogenic cell populations and their mechanisms of action, while focusing mainly on potential exploitation of their tolerogenic mechanisms for clinical applications...
  2. pmc Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer
    Ping Ying Pan
    Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    Cancer Res 70:99-108. 2010
    ..Blockade of CD40-CD40L interaction between MDSC and Treg may provide a new strategy to ablate tumoral immune suppression and thereby heighten responses to immunotherapy...
  3. ncbi request reprint In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery
    Ping Ying Pan
    Carl C Icahn Institute for Gene Therapy and Molecular Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cancer Immunol Immunother 53:17-25. 2004
    ....
  4. doi request reprint Myeloid-derived suppressor cells prevent type 1 diabetes in murine models
    Bingjiao Yin
    Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Immunol 185:5828-34. 2010
    ....
  5. ncbi request reprint Role of immature myeloid Gr-1+ cells in the development of antitumor immunity
    Qingsheng Li
    Carl C Icahn Institute for Gene Therapy and Molecular Medicine, Mount Sinai School of Medicine, New York, New York, USA
    Cancer Res 64:1130-9. 2004
    ....
  6. ncbi request reprint NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation
    Dongping Xu
    Carl C Icahn Institute for Gene Therapy and Molecular Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Cancer 109:499-506. 2004
    ....
  7. doi request reprint Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells
    Zuping Zhou
    Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    Stem Cells 28:620-32. 2010
    ..The successful in vitro generation of MDSCs may represent a critical step toward potential clinical application of MDSCs...
  8. pmc Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function
    Ping Ying Pan
    Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Blood 111:219-28. 2008
    ..This information supports the notion that modulation of MDSC development may be required to achieve effective immune-enhancing therapy for the treatment of advanced tumors...
  9. doi request reprint The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies
    Junko Ozao-Choy
    Departments of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York, USA
    Cancer Res 69:2514-22. 2009
    ..These data suggest that sunitinib can be used to reverse immune suppression and as a potentially useful adjunct for enhancing the efficacy of immune-based cancer therapy for advanced malignancies...
  10. pmc Myeloid-derived suppressor cells as a vehicle for tumor-specific oncolytic viral therapy
    Samuel Eisenstein
    Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cancer Res 73:5003-15. 2013
    ..Our results offer a preclinical proof-of-concept for using MDSCs to facilitate and enhance the tumor-killing activity of tumor-targeted oncolytic therapeutics...
  11. ncbi request reprint Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation
    Ping Ying Pan
    Carl C Icahn Institute for Gene Therapy and Molecular Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Immunol 172:4779-89. 2004
    ....
  12. pmc Paired immunoglobin-like receptor-B regulates the suppressive function and fate of myeloid-derived suppressor cells
    Ge Ma
    Department of Gene and Cell Medicine, Mount Sinai School of Medicine, 1425 Madison Avenue, Room 13 02, New York, NY 10029 6574, USA
    Immunity 34:385-95. 2011
    ..Inhibition of the PIR-B signaling pathway promoted MDSC differentiation into M1 macrophages...
  13. pmc Polarization and reprogramming of myeloid-derived suppressor cells
    Wen Chin Yang
    Department of Oncological Sciences and Immunology Institute, Mont Sinai School of Medicine, New York, NY 10029, USA
    J Mol Cell Biol 5:207-9. 2013
    ..In this article, we summarize and discuss polarization, mechanism and therapeutic potential of MDSC. An emphasis is placed on the emerging concept of reprogramming MDSC polarization as a therapeutic strategy...
  14. ncbi request reprint Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host
    Bo Huang
    Departments of Gene and Cell Medicine and General Surgery, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Cancer Res 66:1123-31. 2006
    ..Our data provide evidence that Gr-1(+)CD115(+) MSC can mediate the development of Treg in tumor-bearing mice and show a novel immune suppressive mechanism by which MSCs can suppress antitumor responses...
  15. ncbi request reprint OX40 ligation enhances primary and memory cytotoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases
    Ping Ying Pan
    Carl C Icahn Institute for Gene Therapy and Molecular Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    Mol Ther 6:528-36. 2002
    ..mIL-12) + anti-4-1BB + anti-OX40 antibodies may provide a better treatment modality for patients with advanced cancers, often associated with a state of immune suppression or tolerance...